PeptideStack
5.2kquestions
20kanswers
220users

Why does aggregation accelerate at 37 °C rather than proceeding linearly?

Asked 7 Sept 2025Modified 7 months agoViewed 6.3k times
14

What I am working with: aggregation · 37 °C.

I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.

My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.

Is the standard explanation correct, and if so, what is the evidence for it?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

832 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

646 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

466 questions
shareeditfollowflag
SW
askedswab_and_wait15k187 Sept 2025

5 Answers

Sorted by votes
25

Stated carefully, freeze-thaw damage happens at the moving ice front, not at the storage temperature. Once the sample is frozen solid and cold, very little is happening. The damage is done during freezing and thawing, which is why the number of cycles matters and the duration of the hold mostly does not.

On re-freezing something that thawed in transit: if it arrived as a lyophilised solid that warmed but never got wet, re-freezing costs you nothing except the thermal cycle. If it arrived as a solution that thawed, re-freezing adds a second transition and therefore a second dose of ice-front shear. The asymmetry is worth internalising.

It helps to be literal here: light matters for specific residues rather than in general. Tryptophan and to a lesser extent tyrosine and methionine are photo-labile; a sequence without them is largely indifferent to ambient light over the timescales in question. Amber glass is cheap insurance rather than a requirement.

The licensed semaglutide and tirzepatide presentations carry in-use periods of several weeks at room temperature in their labelling, which is the closest thing to real stability data in this space — and it applies to a buffered, surfactant-containing, preservative-containing formulation, not to a reconstituted research vial.

The practical rule is that time and temperature multiply, so shorten whichever one you control.

edited 8 Dec 2025 by mira_sundqvist — added the citation requested in comments

shareimprove this answerflag
MS
answeredmira_sundqvist19k186 Dec 2025
8I tested this on two lots and got the same answer, so at least it reproduces. – tabular_nums 2 months ago
The timing signature is the useful part. Everything else is confounded. – vialroom 3 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
16

It helps to be literal here: the honest answer is that published stability data for these specific molecules in a research-grade presentation essentially does not exist, so what you get is extrapolation from the licensed formulations and from general peptide chemistry. That extrapolation is reasonable. It is still extrapolation.

For the solid state, residual moisture is the dominant variable. A cake at two per cent water is considerably more stable than the same cake at six per cent, because water is both a reactant in hydrolysis and a plasticiser that lowers the glass transition temperature. This is why a desiccant in the outer packaging is not theatre, and why opening a cold vial in a humid room is a genuine error — you condense water onto the cake.

To be exact about it, aggregation is the failure mode that reverse-phase HPLC is worst at detecting, because a large soluble aggregate may not elute at all and an insoluble one is filtered out during sample preparation. If your purity result comes back normal but the vial looks hazy, believe the vial. Size-exclusion chromatography is the method that sees this.

Minimise transitions rather than minimising temperature. One freeze and one thaw is fine; five is a different question.

edited 7 Jan 2026 by halvard_ness — clarified the distinction between purity and content

shareimprove this answerflag
HN
answeredhalvard_ness42k3817 Dec 2025
4The placebo-arm figure is the part everyone omits. – rhian_prydderch 6 months ago
add a comment
14

Stated carefully, a warm arrival is a reason to test, not automatically a reason to discard. Peptide degradation is kinetic — rate multiplied by time — and a few days at thirty degrees in the solid state is a small integral compared to weeks in solution.

Practical thermal arithmetic for a shipment: a single 250 g phase-change pack in a thin-walled polystyrene box holds sub-ten-degrees for roughly 24 to 48 hours in a 25 °C ambient, and considerably less at 35 °C. Any lane taking eight to fourteen days is therefore not temperature-controlled for most of its duration regardless of what was in the box, which is the argument for shipping the material lyophilised.

The 28-day figure for a reconstituted preserved vial is microbiological, not chemical. Chemically, a well-behaved peptide at 5 mg/mL at 4 °C will typically lose well under a per cent of content per month. The reason to respect the date is bioburden, and bioburden is a function of how many times you have opened it, not of the calendar.

Worth stating: research-use-only material has no stability programme behind it at all, so any beyond-use date you apply is your own construct.

The single highest-value change most people can make is buying a cheap logging thermometer, because it converts an assumption about their storage into a record.

shareimprove this answerflag
DW
answeredDr_Elias_Weiss46k3828 Dec 2025
8This is the first explanation of that which has actually made sense to me. – RP_C18 9 months ago
Note that the label instructions differ between agents on precisely this point. – meniscus_film 37 days ago
add a comment
11

Start by separating chemical degradation from physical degradation, because they fail differently and they are detected differently. Chemical degradation changes the molecule and shows up as new peaks on a chromatogram. Physical degradation aggregates the molecule and often shows up as nothing at all on reverse-phase HPLC, because the aggregate never makes it onto the column.

Freeze-concentration is the mechanism people miss. As ice forms, everything that is not water is excluded into a shrinking unfrozen fraction, so the local concentration of peptide, buffer salts and preservative rises sharply. If the buffer components crystallise at different rates, local pH can shift by more than a unit. That is why a phosphate-buffered solution can behave badly on freezing while an unbuffered one is fine.

The limitation is that you cannot detect slow aggregation by eye until it is well advanced, so a clear vial is weak evidence of an intact one.

Store solid, store cold, store dry, and reconstitute what you will use rather than what fits in the vial.

shareimprove this answerflag
DV
answeredDr_Bram_Verhoeven85k24810 Sept 2025
7

The lyophilised solid is far more robust than anything anyone says about it, and the solution is far less robust. Most of the confusion in this area comes from advice about one being applied to the other.

A domestic freezer holds roughly minus eighteen degrees and cycles by several degrees on its defrost schedule, which for a lyophilised solid is entirely adequate and for a frozen solution means repeated partial melting at the surface. If you are going to freeze a solution, an unopened chest freezer is materially better than the compartment in the top of a fridge.

If the material arrived warm and it was lyophilised, test it and proceed on the result. If it arrived warm and it was in solution, the result is more likely to be interesting than reassuring.

shareimprove this answerflag
ED
answerede_dziedzic87k24821 Sept 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.